NDA 020248 · Fresenius
Intralipid 20%
Soybean Oil · Injection · Lipid Emulsion
Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Aug 7, 1996
Approved uses
1
Original approval plus efficacy supplements
Registered trials
146
39 Phase 3, 4 recruiting
FAERS reports
727
626 serious, 85 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 8, 2025.
Intralipid ® is indicated as a source of calories and essential fatty acids for adult and pediatric patients requiring parenteral nutrition (PN) and as a source of essential fatty acids for prevention of essential fatty acid deficiency (EFAD). Intralipid is indicated as a source of calories and essential fatty acids for adult and pediatric patients requiring parenteral nutrition (PN) and as a source of essential fatty acids for prevention of essential fatty acid deficiency (EFAD).
Mechanism: Intralipid provides a biologically utilizable source of calories and essential fatty acids. Fatty acids serve as an important substrate for energy production. The most common mechanism of action for energy production derived from fatty acid metabolism is beta oxidation. Fatty acids are also important for membrane structure and function, as precursors for bioactive molecules (such as prostaglandins), and as regulators of gene expression.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 7, 1996 Original approval · Type 3 - New Dosage Form
1 products under this application
- INTRALIPID 20% · SOYBEAN OIL 20% · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Soybean Oil" as an intervention, any sponsor and status, largest first.
- Efficacy of Newborn Vitamin A Supplementation Versus Placebo in Improving Child Survival (NeoVitA Trial)Pivotal-lookingCompleted
Society for Applied StudiesAcademic, hospital or other
NCT01138449 · 44,984 participants · Start Jun 2010 · Primary completion Jun 2013
Drug: Vitamin A · For: Neonatal Vitamin A Supplementation
Sites: New Delhi, India
- Milk Fat Globule Membrane-Enhanced RUTF for Children With Severe Acute MalnutritionPivotal-lookingActive, not recruiting
Washington University School of MedicineAcademic, hospital or other
NCT06869850 · 1,600 participants (planned) · Start Sep 22, 2025 · Primary completion Dec 1, 2027
Drug: Amoxicillin; Sulfadoxine (250 mg)/Pyrimethamine (12.5 mg) · For: Severe Acute Malnutrition; Cognitive Impairment; Kwashiorkor and 1 more
Sites: Bandajuma, Sierra Leone; Bandasuma, Sierra Leone; Bendu Malen, Sierra Leone · 10 sites in all
- Nutritional and Anti-infective Interventions for Malnutrition in Pregnancy (Beleuman Welbodi)Pivotal-lookingCompleted
Washington University School of MedicineAcademic, hospital or other
NCT03079388 · 1,489 participants · Start Feb 27, 2017 · Primary completion Sep 24, 2019
Drug: Monthly intermittent preventive treatment of malaria during pregnancy (IPTp); Standard intermittent preventive treatment of malaria during pregnancy (IPTp) and 2 more · For: Pregnancy; Malnutrition in Pregnancy; Nutrition Disorders and 1 more
Sites: Pujehun, Sierra Leone
- Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With SchizophreniaPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01515423 · 1,429 participants · Start May 2012 · Primary completion Feb 2015
Drug: PP3M 175 mg eq.; PP3M 263 mg eq. and 7 more · For: Schizophrenia
Sites: Little Rock, Arkansas; Glendale, California; Long Beach, California · 174 sites in all
- Comparing Several Strategies to Manage Moderate Acute Malnutrition Among Children From 6 to 24 Months OldPivotal-lookingCompleted
Institut PasteurIndustry
NCT03474276 · 1,357 participants · Start Jan 31, 2018 · Primary completion Dec 31, 2018
Drug: Azythromycin; Albendazole · For: Moderate Acute Malnutrition
Sites: Bangui, Central African Republic; Antananarivo, Madagascar; Maradi, Niger · 4 sites in all
- Assessment of DHA On Reducing Early Preterm BirthPivotal-lookingCompleted
University of Kansas Medical CenterAcademic, hospital or other
NCT02626299 · 1,100 participants · Start Jun 8, 2016 · Primary completion Oct 5, 2020
Drug: Docosahexaenoic acid - 800mg/day; Docosahexaenoic acid - 200mg/day · For: Preterm Birth
Sites: Kansas City, Kansas; Cincinnati, Ohio; Columbus, Ohio
- Prevention of Cognitive Decline in Older Adults With Low Dha/Epa Index in Red Blood CellsPivotal-lookingCompleted
University Hospital, ToulouseAcademic, hospital or other
NCT03691519 · 774 participants · Start Apr 17, 2018 · Primary completion Mar 31, 2020
Drug: Omega-3 treatment · For: Alzheimer Disease
Sites: Toulouse, France
- NB-001 Treatment of Recurrent Herpes LabialisPivotal-lookingStatus unknown
NanoBio CorporationIndustry
NCT01695187 · 362 participants · Start Oct 2012 · Primary completion Jun 2013
Drug: NB-001 (0.3%); Placebo · For: Herpes Labialis
Sites: Chandler, Arizona; Tucson, Arizona; Chicago, Illinois · 12 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- chills75
- pyrexia57
- parenteral nutrition associated liver disease56
- nausea53
- dyspnoea46
- vomiting45
- chest discomfort42
- diarrhoea39
- off label use35
- weight decreased35
- drug ineffective32
- product dose omission issue29
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 1 |
| 2012 | 6 |
| 2013 | 27 |
| 2014 | 49 |
| 2015 | 67 |
| 2016 | 78 |
| 2017 | 65 |
| 2018 | 52 |
| 2019 | 50 |
| 2020 | 44 |
| 2021 | 53 |
| 2022 | 51 |
| 2023 | 60 |
| 2024 | 58 |
| 2025 | 32 |
| 2026 | 29 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Omega-3 fatty acids in parenteral nutrition - A systematic review with network meta-analysis on clinical outcomes.
Pradelli L, Mayer K, Klek S, et al. · Clin Nutr 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- ω-3 PUFA for Secondary Prevention of White Matter Lesions and Neuronal Integrity Breakdown in Older Adults: A Randomized Clinical Trial.
Shinto LH, Murchison CF, Silbert LC, et al. · JAMA Netw Open 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Systematic review of palm oil consumption and the risk of cardiovascular disease.
Ismail SR, Maarof SK, Siedar Ali S, et al. · PLoS One 2018 · Systematic Review
- Evidence-based recommendations on the use of intravenous lipid emulsion therapy in poisoning.
Gosselin S, Hoegberg LC, Hoffman RS, et al. · Clin Toxicol (Phila) 2016 · Systematic Review
- Lipid strategies to prevent intestinal failure-associated liver disease in neonates: A pilot trial.
Huff KA, Cruse W, Vanderpool C · JPEN J Parenter Enteral Nutr 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Medium-chain fatty acids: evidence for incorporation into chylomicron triglycerides in humans.
Swift LL, Hill JO, Peters JC, et al. · Am J Clin Nutr 1990 · Clinical Trial, Randomized Controlled Trial
Sponsor: Fresenius
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.